One Blood Test. Full Disclosure.

GASTROClear is a screening test for early stage stomach cancer. This liquid biopsy test was designed to detect stomach cancer before symptoms appear and to recommend high risk patients for follow-up diagnostic endoscopy.

The test will determine a person’s current risk of having stomach cancer by detecting and measuring a panel of 12 different microRNA molecules. These novel biomarkers are specifically produced by stomach tumours and secreted into the bloodstream.

75% of all new stomach cancer cases occur in Asia. Early diagnosis gives a patient who has stomach cancer the best chance of survival. The ability of GASTROClear to detect stomach cancer has been validated in a 5,000-patient multi-center clinical study carried out in Singapore between 2016 and 2018.

GASTROClear was developed by Ark’s research and development arm, MiRXES Lab,  in collaboration with the Singapore Gastric Cancer Consortium (SGCC), A*STAR’s Diagnostics Development Hub (DxD Hub), National University Hospital (NUH), and Tan Tock Seng Hospital (TTSH).